Differential genetic and functional markers of second neoplasias in Hodgkin's disease patients

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4823-4828

  Lorenzo, Yolanda ^a   Provencio, Mariano ^a   Lombardía, Luís ^b   Díaz, Raquel ^a   Silva, Javier ^a   Herrera, Mercedes ^a   García, Jose M ^a   Peña, Cristina ^a   García, Vanesa ^a   Romero, Jesús ^a   Domínguez, Gemma ^a   Bonilla, Félix ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 40; RAD50 PROTEIN; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR T BET;

ADOLESCENT; ADULT; ARTICLE; CANCER GENETICS; COMET ASSAY; DNA DAMAGE; DNA HYBRIDIZATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENETIC MARKER; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECOND CANCER;

ADOLESCENT; ADULT; AGED; CHILD; DNA DAMAGE; DNA REPAIR; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 68049133170     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3224     Document Type: Article

References (38)

1. Hodgkin T. On some appearances of the absorbent glands and spleen. Med Chi Trans 1832;17: 69-114.
2. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center Ccells. N Engl J Med 1997;337:453-458 (Pubitemid 27333046)
3. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-3113 (Pubitemid 29512717)
4. Stein H, Marafioti T, Foss HD, et al. Downregulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001;97: 496-501. (Pubitemid 32060336)
5. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989; 320:689-695 (Pubitemid 19072487)
6. Weiss LM, Mohaved LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-506 (Pubitemid 19062526)
7. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridation. Blood 1989;74:810-816 (Pubitemid 19208827)
8. Volker D. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. J Clin Oncol 2004;22:15-18
9. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-3439
10. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-325 (Pubitemid 24056405)
11. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995;87:1530-1537
12. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001;19:1610-1618 (Pubitemid 32230860)
13. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192 (Pubitemid 34162752)
14. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willet CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997; 79:1203-1210
15. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-980 (Pubitemid 36896714)
16. Ng AK, Mauch PM. The impact of treatment on the risk of second malignancy after Hodgkin's disease. Ann Oncol 2006;17:1727-1729 (Pubitemid 44884044)
17. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-897 (Pubitemid 30429188)
18. Cleaver JE, Charles WC, McDowell ML, Sadinski WJ,Mitchell DL. Overexpression of the XPA repair gene increases resistance to ultraviolet radiation in human cells by selective repair of DNA damage. Cancer Res 1995;55:6152-6160
19. Dores GM, Metayer C, Curtis RE, et al. Secondmalignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-3494
20. Lorigan P, Radford J, Howell A, et al. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol 2005;6:773-779 (Pubitemid 41430718)
21. Van Leeuwen FE, Travis LB. Second Cancer. In: DeVita VT, Hellman S, editors. Cancer: Principles & Practice of Oncology. 7th ed. Philadelphia: Lippincott William & Wilkins, Rosenberg SA; 2005. p. 2575-2602
22. Provencio M, Corbacho C, Salas C, et al. The topoisomerase II α expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 2003;9:1406-1411 (Pubitemid 36418394)
23. ProvencioM, España P,Salas C,Navarro F, Bonilla F. Hodgkin's disease: correlation between causes of death at autopsy and clinical diagnosis. Ann Oncol 2000;11:59-64. (Pubitemid 30084580)
24. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individuals cells. Exp Cell Res 1988;175:184-189
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Society B 1995;57:289-300.
26. Domínguez G, García JM, Peña C, et al. ΔTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53 and E2F-1. J Clin Oncol 2006;24:805-815 (Pubitemid 46622048)
27. Willits I, Price L, Parry A, et al. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the Comet Assay in children with cancer. Br J Cancer 2005;92:1626-1635 (Pubitemid 40756472)
28. Lee TK, Allison RR, O'Brien KF, et al. Persistence of micronuclei in lymphocytes of cancer patients after radiotherapy. Radiat Res 2002; 157:678-684 (Pubitemid 34569136)
29. Gamulin M, Kopjar N, Grgic M, et al. Genome damage in oropharyngeal cancer patients treated by radiotherapy. Croat Med J 2008;49:515-527
30. Nothdurft W, Fliedner TM, Fritz TE, et al. Response of hemopoiesis in dogs to continuous low dose rate total body irradiation. Stem Cells 1995;13:261-267
31. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim Biophys Acta 2002;1602: 131-150 (Pubitemid 34521792)
32. Atayar C, Poppema S, Blokzijl T, Harms G, Boot M, van den Berg A. Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol 2005;166:127-134 (Pubitemid 40051666)
33. Zullo AJ, Benlagha K, Bendelac A, Taparowsky EJ. Sensitivity of NK1.1-negative NKT cells to transgenic BATF defines a role for activator protein- 1 in the expansion and maturation of immature NKT cells in the thymus. J Immunol 2007; 178:58-66. (Pubitemid 46033587)
34. Ehrhardt A, Ehrhardt GR, Guo X, Schrader JW. Ras and relatives -job sharing and networking keep an old family together. Exp Hematol 2002; 30:1089-1106
35. Dorfman DM, Hwang ES, Shahsafaei A, Glimcher LH. T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma. Hum Pathol 2005;36:10-15 (Pubitemid 40215628)
36. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002;300:361-366
37. Schmiegelow K, Björk O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukaemia. J Clin Oncol 2003;21:1332-1339 (Pubitemid 46606412)
38. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564-1572 (Pubitemid 30770506)